Chapter 1 28 45. Prise KM, Schettino G, Folkard M, Held KD. New insights on cell death from radiation exposure. Lancet Oncol 2005;6:520–8. 46. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009;10:718–26. 47. Barnett GC, West CML, Dunning AM, Elliott RM, Coles CE, Pharoah PDP, et al. Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype. Nat Rev Cancer 2009;9:134–42. 48. Kamran SC, Light JO, Efstathiou JA. Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care. Prostate Cancer Prostatic Dis 2019;22:509–21. 49. Zaorsky NG, Davis BJ, Nguyen PL, Showalter TN, Hoskin PJ, Yoshioka Y, et al. The evolution of brachytherapy for prostate cancer. Nat Rev Urol 2017;14:415–39. 50. Georg D, Hopfgartner J, Gòra J, Kuess P, Kragl G, Berger D, et al. Dosimetric considerations to determine the optimal technique for localised prostate cancer among external photon, proton, or carbon-ion therapy and high-dose-rate or low-doserate brachytherapy. Int J Radiat Oncol Biol Phys 2014;88:715–22. 51. Bortfeld T. IMRT: a review and preview. Phys Med Biol 2006;51:R363-79. 52. Musunuru HB, Cheung P, Loblaw A. Evolution of hypofractionated accelerated radiotherapy for prostate cancer - the sunnybrook experience. Front Oncol 2014;4:313. 53. Moraes FY de, Siqueira GMS de, Abreu CECV, da Silva JLF, Gadia R. Hypofractioned radiotherapy in prostate cancer: is it the next step? Expert Rev Anticancer Ther 2014;14:1271–6. 54. Hegemann N-S, Guckenberger M, Belka C, Ganswindt U, Manapov F, Li M. Hypofractionated radiotherapy for prostate cancer. Radiat Oncol 2014;9:275. 55. van Leeuwen CM, Oei AL, Crezee J, Bel A, Franken NAP, Stalpers LJA, et al. The alfa and beta of tumours: a review of parameters of the linear-quadratic model, derived from clinical radiotherapy studies. Radiat Oncol 2018;13:96. 56. Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, noninferiority, phase 3 trial. Lancet 2019;394:385–95. 57. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 2019;20:1531–43. 58. Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, et al. Stereotactic Body Radiotherapy for Localised Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. Int J Radiat Oncol 2019;104:778– 89. 59. Pathmanathan AU, van As NJ, Kerkmeijer LGW, Christodouleas J, Lawton CAF, Vesprini D, et al. Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A “Game Changer” for Prostate Treatment? Int J Radiat Oncol Biol Phys 2018;100:361– 73. 60. de Muinck Keizer DM, Pathmanathan AU, Andreychenko A, Kerkmeijer LGW, van der Voort van Zyp JRN, Tree AC, et al. Fiducial marker based intrafraction motion assessment on cine-MR for MR-Linac treatment of prostate cancer. Phys Med Biol 2019;64:07NT02. 61. de Muinck Keizer DM, Kerkmeijer LGW, Maspero M, Andreychenko A, van der Voort van Zyp JRN, van den Berg CAT, et al. Soft-tissue prostate intrafraction motion tracking in 3D cine-MR for MR-guided radiotherapy. Phys Med Biol 2019;64:235008. 62. de Muinck Keizer DM, Kerkmeijer LGW, Willigenburg T, van Lier ALHMW,, et al. Prostate intrafraction motion during the preparation and delivery of MRguided radiotherapy sessions. Radiother Oncol 2020;151:88–94. 63. Kontaxis C, de Muinck Keizer DM, Kerkmeijer LGW, Willigenburg T, den Hartogh MD, van der Voort van Zyp JRN, et al. Delivered dose quantification in prostate radiotherapy using online 3D cine imaging and treatment log files on a combined 1.5T magnetic resonance imaging and linear accelerator system. Phys Imaging Radiat Oncol 2020;15. 64. Lagendijk JJW, Raaymakers BW, Raaijmakers AJE, Overweg J, Brown KJ, Kerkhof EM, et al. MRI/linac integration. Radiother Oncol 2008;86:25–9. 65. Lagendijk JJW, Raaymakers BW, van Vulpen M. The Magnetic Resonance Imaging–Linac System. Semin Radiat Oncol 2014;24:207–9. 66. Raaymakers BW, Lagendijk JJW, Overweg J, Kok JGM, Raaijmakers AJE, Kerkhof EM, et al. Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept. Phys Med Biol 2009;54:N229-37.
RkJQdWJsaXNoZXIy MTk4NDMw